Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

HAVN Life Sciences Continues To Execute On Growth Initiatives Ahead Of Its Upcoming Public Listing

Jun 30, 2020 • 7:40 AM EDT
5 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

We have seen a substantial increase in interest in psychedelic focused businesses during the last month and this is a trend that our readers need to be aware of.

The psychedelic sector has recently come under pressure and we encourage our readers to conduct significant due diligence on companies in the space. Recent issues have highlighted the importance of being selective when it comes to this sector such that our readers need to focus on businesses that own legitimate assets and that are led by a management teams that acts in the best interest of shareholders.

Today, we want to highlight a psychedelic company that has caught our attention and is one that we are closely following. The company, HAVN Life, is a psychedelic development business that has a multi-pronged growth strategy and is an opportunity to have on your radar. The company has been conducting and supporting research and development of microdosing therapies in treating mental health disorders with psychedelics.

A Differentiated Growth Story to be Aware Of  

HAVN Life is laser focused on generating sustainable revenue through its retail brands that are based on novel psychoactive compounds. The company plans to conduct research in a state-of-the-art mycology lab to create proprietary formulations and we are favorable on the strategy that is in place for growth.

Another way that HAVN Life has been able to differentiate itself from its peers is through the structure of the business. The company represents a multi-faceted growth opportunity that is comprised of two divisions (HAVN Labs and HAVN Retail) that could create significant value for each other over the long-term.

HAVN Labs is Executing on High-Level Growth Initiatives

Through HAVN Labs, the company will have access to a laboratory that is focused on the advancement and formulation of regulated psychoactive compounds. The division will operate out of a state-of-the-art facility that is based at The University of British Columbia and will be used for advanced formulation development, standardization testing and quality control.

The facility will have a licensed mycology laboratory that will have the ability to expand into a pilot plant without having to move to another facility. The laboratory will provide HAVN Labs with the opportunity to formulate and manufacture products in one location and are favorable on this aspect of the story.

One of the most important aspects of HAVN Life is related to the application that was submitted to Health Canada for a research license. The company expects to be granted the license within the next several months and this would prove to be a major catalyst for the business. The granting of the license will allow for the research and development of psychedelic compound formulations to begin prior to securing a Licensed Dealer status. In 2021, HAVN Life expects to be granted this designation which will enable the company to supply and sell regulated compounds.

The current access to research informed formulations is limited and HAVN Labs plans to provide standardized psychedelic compound formulations to academic institutions that will be utilized for clinical trials and as Active Pharmaceutical Ingredients (APIs) for products.

HAVN Retail Provides the Business with a Quick Path for Revenue Growth

Through HAVN Life’s unique IP and custom formulations, the company plans to enter the natural health food and nutraceutical industry. These burgeoning verticals will provide the business with significant revenues and consistent growth and we are bullish on this aspect of the business.

HAVN Life will be developing novel intellectual property (IP), where these formulations will be sold through HAVN Retail and will provide increased mindfulness, decreased stress and anxiety, and an uplifted mood.

An important aspect of the HAVN Retail vertical is related to how it will bring products to market. The initial psychoactive microdosing products that will be sold by HAVN Life will be derived from novel psychoactive compounds. These products will not require the Health Canada Licensed Dealer status and we find this to be of importance.

HAVN Life has a multi-phased approach for growing the retail business and we are favorable on the strategy that is in place. In the first phase, HAVN Retail will formulate and sell products through online retailers and on its website. The company plans to leverage the experience of the management team to build NHP brands and we are favorable on the direction that the team is taking the business. HAVN Life plans to secure NHP licenses as formulations for retail product lines grow and we expect the management team to play an important role in this.

An Emerging Growth Story of which to be Aware

When we first started to research HAVN Life, we were initially impressed with the strength of management team and found this this to be an attractive aspect of the story. The team is comprised of individuals who are leaders in their respective fields and we are favorable on the diversity of the team from an expertise standpoint.

HAVN Life is in the final stages of product development and expects to have products available in nutraceutical retailers later this year. We are bullish on the growth prospects that are associated with this timeline and will monitor how the management team is able to drive the story forward.

HAVN Life is privately held and plans to complete a go-public transaction in the near future. Over the next year, we expect to see the company’s divisions to record substantial developments and are bullish on the amount of value and the amount of synergies that can be generated between these assets.

If you are interested in learning more about HAVN Life, please send an email to support@mushroomstocks.com to be added to our distribution list.







Pursuant to an agreement between StoneBridge Partners LLC and HAVN Life Sciences we have been hired for a period of 180 days beginning June 1, 2020 and ending December 1, 2020 to publicly disseminate information about (HAVN) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (HAVN) for or were paid “0” shares of restricted common shares. We own zero shares of (HAVN), which we purchased in the open market. We plan to sell the “ZERO” shares of (HAVN) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (HAVN) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.